Celf4 mutant zebrafish white matter porosity model and application thereof

The celf4 mutant zebrafish model was constructed through CRISPR/Cas9 technology, which solved the high cost and difficulty of observation of rodent models, established an efficient leukoplasmic loosening model, and provided a high-throughput drug screening platform to improve neurodegeneration Efficiency of sexual disease research and drug development.

CN119061014AInactive Publication Date: 2024-12-03NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411445992.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-16
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing rodent models are used to study the high feeding cost, long cycle and difficult observation of leukoplasmic looseness diseases. Whether the ischemia and hypoxia models accurately simulate the disease mechanism has not been clarified, and there is a lack of an efficient drug screening platform.

Method used

The celf4 mutant zebrafish model was constructed through CRISPR/Cas9 technology to simulate the pathological characteristics of human leukoplasmic looseness, and use the short development cycle, low cost and high transparency of zebrafish to establish a leukoplasmic looseness model, and combine it with a high-throughput drug screening platform.

Benefits of technology

It has achieved rapid and low-cost construction of leukostasis models and drug screening, improved the depth of disease mechanism research and drug development efficiency, and provided an efficient and low-cost experimental platform.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061014A_ABST
    Figure CN119061014A_ABST
Patent Text Reader

Abstract

The invention discloses a celf4 mutant zebrafish white matter looseness model which can cause white matter lesion based on celf4 mutation and is constructed based on a CRISPR / Cas9 technology and application of the celf4 mutant zebrafish white matter looseness model. The invention discovers that the celf4 gene mutation is related to the white matter for the first time, and the celf4 mutant has a phenotype similar to the loose white matter of the human brain. According to the model, the celf4 gene in the zebrafish is specifically knocked out, the pathological characteristics of human white matter looseness are simulated, and a novel animal model is provided for research on neurodegenerative diseases and white matter damage. Compared with a traditional rodent model, the built zebrafish model has the advantages of being short in development cycle, high in transparency, high in reproduction rate, low in cost and the like, and large-scale genetic screening and dynamic observation are facilitated. In addition, the model can also be applied to drug screening, and an efficient and low-cost experimental platform is provided for research and development of nervous system disease treatment drugs. Implementation of the invention is of great significance in deeply revealing the pathological mechanism of white matter looseness and accelerating research and development of related drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and specifically to constructing a celf4 mutant based on relevant transgenic zebrafish to establish a leukoaraiosis model, which can be used to study the occurrence mechanism of neurodegenerative diseases and white matter damage and drug screening. Background Art

[0002] Leukoaraiosis is a characteristic of a class of neurological diseases, the main feature of which is the damage or reduction of the myelin sheath in the brain. The myelin sheath is a layer composed of lipids and proteins that protects the axons of nerve cells, helping to conduct nerve signals and maintain the function of the nervous system. Leukoaraiosis is an important factor leading to dementia, sleep disorders and mood disorders. In many neurological diseases, such as multiple sclerosis (MS), leukoencephalopathy, cerebral small vessel disease, vascular dementia, etc., leukoaraiosis is one of the important pathological features of the disease. However, its pathological mechanism is still unclear and there is no effective drug treatment.

[0003] The lag in research is closely related to the complexity of model construction. Currently, leukoaraiosis mainly relies on complex rodent models, such as mice and rats, which are mostly based on vascular ischemia and hypoxia. However, these models have several significant limitations and challenges: long cycle and high cost: the breeding cycle of rodents is relatively long, and the cost of feeding and maintenance is high. In addition, the long experimental cycle limits the research needs of large-scale screening and rapid iteration. Difficulty of observation: Despite the continuous development of modern imaging technology, it is still challenging to directly observe subtle changes in the nervous system in living rodents, especially the dynamic changes of deep structures such as white matter. In addition, ischemia and hypoxia are important risk factors for leukoaraiosis, but whether they are the key factors of leukoaraiosis is not yet known.

[0004] Zebrafish (Danio rerio) is a widely used model organism in biomedical research. Zebrafish embryos mature in a short period of time, and the transparency of their embryos and larvae allows researchers to visually observe the morphology of organs and tissues. Zebrafish also have a high reproduction rate and relatively low feeding costs, making them one of the preferred animal models for research. In recent years, scientists have begun to use zebrafish as a model to study neurological diseases, but its leukoaraiosis model has not yet been reported.

[0005] The CELF4 (CUGBP Elav-like family member 4) gene belongs to the CUGBP / Elav-like family, and members of this family play an important role in RNA processing and regulation. Specifically, CELF4 is involved in the regulation of RNA splicing, stability, translation, and intracellular localization. Since RNA processing and regulation are essential for the function and development of nerve cells, abnormalities in CELF4 may affect the normal function of the nervous system. CELF4 is highly expressed in the nervous system, especially in key areas such as the brain and spinal cord. This suggests that it may play an important role in the development and function of the nervous system. The high expression characteristics make CELF4 an important candidate gene for studying neurological diseases. The potential association of CELF4 with neurological diseases. Studies have shown that mutations or abnormal expression of CELF4 are associated with certain neurological diseases. For example, the role of CELF4 in epilepsy, neurodegenerative diseases, and cognitive impairment has been preliminarily studied. The discovery that mutations in CELF4 are associated with leukoaraiosis can provide new clues for studying the mechanism of this disease. Summary of the invention

[0006] The present invention relates to the field of biomedicine, and specifically discloses a zebrafish leukoaraiosis model based on celf4 mutation that can cause leukoaraiosis and a celf4 mutant constructed based on CRISPR / Cas9 technology and its application. The present invention first discovered that celf4 gene mutation is related to leukoaraiosis, and celf4 mutants have a phenotype similar to human leukoaraiosis. The model simulates the pathological characteristics of human leukoaraiosis by specifically knocking out the celf4 gene in zebrafish, and provides a new animal model for the study of neurodegenerative diseases and leukoaraiosis. Compared with traditional rodent models, the zebrafish model established by the present invention has the advantages of short development cycle, high transparency, fast reproduction rate, low cost, etc., which is convenient for large-scale genetic screening and dynamic observation. In addition, the model can also be applied to drug screening, providing an efficient and low-cost experimental platform for the research and development of drugs for the treatment of nervous system diseases. The implementation of the present invention is of great significance for deeply revealing the pathological mechanism of leukoaraiosis and accelerating the research and development of related drugs.

[0007] The present invention aims to establish a zebrafish leukoaraiosis model and apply it to drug screening to solve the following problems in neurological disease research and drug development:

[0008] 1. Lack of effective experimental models: Currently, research on neurological diseases usually relies on mammalian models such as mice, which have problems such as high breeding costs, long cycles and limited numbers. The present invention provides a new method using zebrafish as an experimental model, which has advantages including short cycles, high reproduction rates and easy observation, and can effectively make up for the shortcomings of existing models.

[0009] 2. Lack of high-throughput drug screening platform: Traditional drug screening methods are usually time-consuming and costly. The present invention uses the zebrafish leukoaraiosis model to provide a high-throughput drug screening basis that can test the effects of multiple compounds at the same time and accelerate the drug development process.

[0010] In order to achieve the above-mentioned invention object, the present invention adopts the following technical scheme:

[0011] 1. The product formula required for preparing the celf4 mutant zebrafish leukoaraiosis model includes: 300ng / μL Cas9 protein, 50ng / μL celf4 sgRNA.

[0012] 2. The preparation process of the celf4 mutant zebrafish leukoaraiosis model includes:

[0013] Step 1: Synthesize sgRNA

[0014] The required materials include:

[0015] 2.5μL p MD 19-T vector (1.5ng / μL), 2.5μL sg RNAForward, 2.5μL sg RNAreverse primer, 25μL 2X Taq PCR master Mix, 17.5μL DEPC H2O, DNAclean&concentrator kit, Megashortscript TM kit.

[0016] The specific steps include:

[0017] 1) Mix the reaction components to a total volume of 50 μL and perform PCR amplification.

[0018] 2) The amplified product was purified using a DNA clean & concentrator kit (Zymo Research).

[0019] 3) After purification, sg RNA was synthesized in vitro using the Megashortscript TM kit and incubated at 37°C for 2 hours.

[0020] 4) Add 1 μl of TURBO DNase, mix by brief centrifugation in a microcentrifuge, and incubate at 37°C for 15 min.

[0021] 5) Purify sgRNA and confirm by agarose gel electrophoresis.

[0022] Step 2: Mix Cas9 protein and sgRNA

[0023] The required materials include: 1μL Cas9 protein, 1μL sgRNA.

[0024] The specific steps include: mixing Cas9 and sgRNA on ice and incubating for 10 minutes.

[0025] Step 3: Microinjection

[0026] The required materials include: transgenic zebrafish fertilized eggs from a cross between Tg(olig2:dsred) and Tg(sox10:egfp), and 2 μL of Cas9 / sgRNA mixture.

[0027] The specific steps include:

[0028] 1) Inject Cas9 / sgRNA into fertilized eggs at the 1-4 cell stage.

[0029] 2) Culture at 28°C.

[0030] Step 4: Screening and Validation

[0031] Required materials: zebrafish larvae 48 hours after injection.

[0032] The specific steps include:

[0033] 1) Screening of successfully mutated zebrafish by PCR and Sanger sequencing.

[0034] 2) Use confocal microscopy to observe Tg(olig2:dsred;sox10:egfp) cells co-labeled with red and green fluorescence.

[0035] 3) The mutants are raised and cultured for two generations, and the pure F2 generation is selected. In each generation, fluorescent zebrafish with Tg (olig2: dsred; sox10: egfp) need to be selected.

[0036] 4) Use fluorescence microscopy to observe pure mutant zebrafish and evaluate the effects of mutations on labeled cells. Transgenic fish Tg(olig2:dsred;sox10:egfp) were used to observe changes in myelin sheaths and oligodendrocytes, the cells that make up myelin sheaths. In Tg(olig2:dsred;sox10:egfp), green fluorescence egfp and red fluorescence dsred were co-labeled to represent oligodendrocytes.

[0037] 3. Process conditions

[0038] The temperature of the whole process is: 28℃.

[0039] The time for sgRNA synthesis is: 2 hours.

[0040] The culture time after injection is: 72 hours.

[0041] 4. Product application methods and results

[0042] The application method is: placing the F2 generation pure strain celf4 mutant on a 96-well plate, applying 0.1-100 μM of the drug to be screened, and timely observing and evaluating the therapeutic effect of the drug on leukoaraiosis according to the required observation indicators and time points.

[0043] The product results are: in the Tg (olig2: dsred; sox10: egfp) model carrying the celf4 mutant, by applying different drugs, observing the changes in the neurodevelopmental and behavioral characteristics of zebrafish embryos, such as observing the recovery of motor ability, oligodendrocytes or myelin sheaths after 5 days, etc., to screen reliable drugs.

[0044] Beneficial effects:

[0045] The effects and advantages created by the present invention are as follows:

[0046] 1. Advantages of establishing zebrafish leukoaraiosis model:

[0047] High efficiency: By combining transgenic zebrafish with mutant celf4, a leukoaraiosis model can be established with only simple gene editing. Compared with traditional mammalian models, the experimental operation time is greatly reduced, which improves the experimental efficiency.

[0048] Low cost: The cost of raising zebrafish is relatively low, and their reproduction rate is high, so they can be produced on a large scale, reducing experimental costs.

[0049] Visualization: Transgenic fish Tg (olig2:dsred; sox10:egfp) visualize myelin-forming cells, oligodendrocytes, which facilitates intuitive observation of myelin changes and helps to conduct in-depth research on disease mechanisms.

[0050] 2. Provides an important carrier for drug screening:

[0051] High throughput: The zebrafish leukoaraiosis model provides a platform for high-throughput drug screening, which can test the effects of multiple compounds simultaneously and accelerate the drug screening process.

[0052] Improved accuracy: By simulating leukoaraiosis in vivo, the efficacy of compounds can be more effectively evaluated and the screening accuracy can be improved.

[0053] Save resources: Compared with traditional drug screening methods, the zebrafish model requires less reagents and sample volume, saving raw materials and resource consumption. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figure 1.1:The site of sgRNA in the construction of celf4 sgRNA; Figure 1.2 : F0 sequencing results of sgRNA.

[0055] Figure 2 :Myelin sheaths of celf4 mutants are damaged. This figure shows the results of transmission electron microscopy of celf4 mutant zebrafish to observe the myelin sheaths in the white matter of the brain. The results showed that myelin sheaths were reduced in the white matter of celf4 mutant zebrafish, indicating that the leukoaraiosis model was successfully simulated.

[0056] Figure 3 :In the celf4 mutant, Tg(olig2:dsred;sox10:egfp) oligodendrocytes are reduced. The celf4 mutant Tg(olig2:dsred;sox10:egfp) transgenic markers were used to observe the oligodendrocytes in the zebrafish brain. Red and green co-labeling indicates oligodendrocytes, and the reduction of oligodendrocytes is an important feature of leukoaraiosis.

[0057] Figure 4 :There was no significant difference in the proliferation of neural progenitor cells in celf4 mutants. The expression of neural progenitor cell markers olig2 and mitotic cell marker PH3 in the control group and celf4 mutants was observed by immunofluorescence staining. The results showed that celf4 mutants had no significant effect on the proliferation of neural progenitor cells.

[0058] Figure 5 :Behavioral results show abnormal behavior in celf4 mutant zebrafish. AC) Distance traveled, acceleration recording duration, turning angle and other indicators of zebrafish behavior change (5-day results). DETAILED DESCRIPTION

[0059] The present invention will be further explained below in conjunction with the embodiments.

[0060] Example 1: Synthesis and purification of sgRNA

[0061] Prepare the following materials:

[0062] 2.5μL p MD 19-T vector (1.5ng / μl), 2.5μL sg RNA forward primer, 2.5μL sg RNA reverse primer, 25μL 2X Taq PCR master Mix, 17.5μL DEPC H2O, DNA clean & concentrator kit, Megashortscript TM kit.

[0063] The steps include:

[0064] 1) Mix the reaction components in a total volume of 50 μL and perform PCR amplification.

[0065] 2) 5 μL of the amplified product was detected by agarose gel electrophoresis, and the remainder was purified and recovered using a DNA clean & concentrator kit (Zymo Research).

[0066] 3) After purification, sgRNA was synthesized in vitro using the Megashortscript TM kit and incubated at 37°C for 2 hours.

[0067] 4) Add 1 μl of TURBO DNase, mix by brief centrifugation in a microcentrifuge, and incubate at 37°C for 15 min to remove the template DNA.

[0068] 5) Purify sgRNA by phenol / chloroform extraction and ethanol precipitation, and confirm by agarose gel electrophoresis.

[0069] Example 2: Mixing and microinjection of Cas9 protein and sgRNA

[0070] Prepare the following materials:

[0071] 1μL Cas9 protein (300ng / μL), 1μL purified celf4 sgRNA (about 50ng / μL), transgenic zebrafish fertilized eggs from the hybrid of Tg(olig2:dsred) and Tg(sox10:egfp), and a microinjection system (including a micromanipulator, injection needle, etc.).

[0072] The steps include:

[0073] 1) On ice, gently mix 1 μL Cas9 protein with 1 μL sgRNA, avoiding bubbles, and incubate for 10 minutes. Using a microinjection system, inject 2 nL of the Cas9 / sgRNA mixture into 1-4 cell stage fertilized eggs.

[0074] 2) The injected fertilized eggs were placed in a constant temperature incubator at 28°C for culture.

[0075] Example 3: Screening and verification of mutant zebrafish

[0076] Prepare the following materials:

[0077] Zebrafish larvae 48 hours after injection, PCR primers (designed for the celf4 gene editing site), DNA extraction kit, and fluorescence microscope.

[0078] The steps include:

[0079] 1) Genomic DNA was extracted from zebrafish larvae 48 hours after injection.

[0080] 2) Use the designed PCR primers for PCR amplification, and send the product for sequencing to confirm the editing of the celf4 gene.

[0081] 3) The zebrafish with successful mutations were screened and continued to be raised to the F2 generation. In each generation, zebrafish with Tg (olig2: dsred; sox10: egfp) fluorescence were screened by PCR and fluorescence microscopy.

[0082] 4) Use confocal microscopy and transmission electron microscopy to observe the fluorescence expression and myelin formation of F2 generation purebred mutant zebrafish, and evaluate the effect of celf4 mutation on oligodendrocytes and myelin.

[0083] Example 4: Drug screening experiment

[0084] Prepare the following materials:

[0085] F2 generation purebred celf4 mutant zebrafish, drugs to be screened (such as neuroprotectants, anti-inflammatory drugs, etc.), concentration gradient of 0.1-100 μM, 96-well plate, fluorescence microscope.

[0086] The steps include:

[0087] 1) F2 generation purebred celf4 mutant zebrafish were placed in 96-well plates, and different drug concentration gradients were set for each group.

[0088] 2) At a specific time point (e.g., 5 days), use fluorescence microscopy to observe the recovery of zebrafish's motility, oligodendrocytes (observed by Tg(olig2:dsred;sox10:egfp) fluorescence) and myelin (observed by transmission electron microscopy).

[0089] 3) Record and analyze data to evaluate the therapeutic effects of different drugs on leukoaraiosis.

Claims

1. A celf4 mutant zebrafish leukoaraiosis model, characterized in that: Ingredients: 300ng / μL Cas9 protein, 50ng / μL celf4 sgRNA.

2. The method for preparing the celf4 mutant zebrafish leukoaraiosis model according to claim 1, characterized in that: The following steps are included: Step 1: Synthesize sgRNA. The specific steps include: Step 1.1: Mix pMD 19-T vector, sg RNAForward, sg RNAreverse primer, 2X TaqPCRmaster Mix, and DEPC H2O for PCR amplification; Step 1.2: Purify the amplified product using a DNAclean&concentrator kit; Step 1.3: Use the Megashortscript™ kit to synthesize sg RNA in vitro using the purified amplification product and incubate; Step 1.4: Add TURBO DNase to the product obtained in step 1.3, mix well and incubate; Step 1.5: Purify the product obtained in step 1.4 and confirm it by agarose gel electrophoresis; Step 2: Mix the Cas9 protein and the purified sgRNA obtained in step 1 and incubate them to obtain a Cas9 / sgRNA mixture; Step 3: Inject the Cas9 / sgRNA mixture into 1-4 cell stage transgenic zebrafish fertilized eggs from the cross between Tg(olig2:dsred) and Tg(sox10:egfp) and culture them; Step 4: Screen the zebrafish with successful mutations from the zebrafish fry and continue to raise them to the F2 generation. In each generation, screen the zebrafish with Tg (olig2: dsred; sox10: egfp) fluorescence by PCR and fluorescence microscopy; Step 5: Observe the fluorescence expression and myelin formation of the F2 generation purebred mutant zebrafish to evaluate the effect of celf4 mutation on oligodendrocytes and myelin.

3. The preparation method according to claim 2, characterized in that: In step 1.1, the volumes of p MD 19-T vector, sgRNA Forward, sg RNA reverse primer, 2X Taq PCR master Mix, and DEPC H2O are 2.5 μL, 2.5 μL, 2.5 μL, 25 μL, and 17.5 μL, respectively, and the plasmid concentration of p MD 19-T vector is 1.5 ng / μl.

4. The preparation method according to claim 2, characterized in that: In step 2, the plasmid concentrations of Cas9 protein and celf4sgRNA were 300 ng / μL and 50 ng / μL, respectively.

5. The preparation method according to claim 2, characterized in that: The volume of the Cas9 / sgRNA mixture in step 3 is 2 μL.

6. The preparation method according to claim 2, characterized in that: Step 4 specifically includes: 1) Screening of successfully mutated zebrafish by PCR and Sanger sequencing; 2) Use confocal microscopy to observe Tg(olig2:dsred;sox10:egfp) cells co-labeled with red and green fluorescence; 3) The mutants are raised and cultured for two consecutive generations, and the purebred F2 generation is selected; fluorescent zebrafish with Tg (olig2: dsred; sox10: egfp) must be selected in each generation.

7. The preparation method according to claim 2, characterized in that: Step 5 specifically includes: Purebred mutant zebrafish were observed using a fluorescence microscope to evaluate the effects of mutations on labeled cells. Transgenic fish Tg(olig2:dsred;sox10:egfp) were used to observe changes in myelin sheaths and oligodendrocytes, the cells that make up the myelin sheath. In Tg(olig2:dsred;sox10:egfp), green fluorescence egfp and red fluorescence dsred were co-labeled to represent oligodendrocytes.

8. The preparation method according to claim 2, characterized in that: The temperature of the entire process is: 28°C; the time for sgRNA synthesis is: 2 hours; the time for culture after injection is: 72 hours.

9. Use of the celf4 mutant zebrafish leukoaraiosis model prepared by the preparation method according to any one of claims 2 to 8, characterized in that: The purebred celf4 mutant of the F2 generation is placed in a 96-well plate, and 0.1-100 μM of the drug to be screened is applied at the same time, and the therapeutic effect of the drug on leukoaraiosis is observed and evaluated in a timely manner according to the required observation indicators and time points.